Neurothera Labs Inc. (TSXV:NTLX)

Neurothera Labs Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024
Period Ending	Dec 31, 2025	Dec 31, 2024
Net Income	-4.12	-2.94
Depreciation & Amortization	0.19	0.37
Asset Writedown & Restructuring Costs	0.12	1.34
Stock-Based Compensation	0.38	0.05
Other Operating Activities	1.22	-1.19
Change in Accounts Receivable	-	0.01
Change in Inventory	0.04	0.63
Change in Accounts Payable	0.2	-0.03
Change in Other Net Operating Assets	0.31	0.08
Operating Cash Flow	-1.66	-1.69
Cash Acquisitions	0.71	-
Other Investing Activities	-	-0.01
Investing Cash Flow	0.71	-0.01
Long-Term Debt Issued	1.14	-
Net Debt Issued (Repaid)	1.14	-
Issuance of Common Stock	1.39	1.66
Financing Cash Flow	2.53	1.66
Net Cash Flow	1.58	-0.03
Levered Free Cash Flow	-0.41	-
Unlevered Free Cash Flow	-0.33	-
Change in Working Capital	0.55	0.69

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jun 15, 2026

Data Sources Report a data error